Acute Caffeine Intake in Older Adults

NCT07711665 | Completed

• 1 other identifier: CEIP/2022/3/055_1
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

Evidence regarding the ergogenic effects of caffeine is well-established in young adults, but evidence in older adults remains scarce, particularly during dynamic resistance exercise. Therefore, this study investigated the effects of acute caffeine ingestion on upper- and lower-body muscular strength and endurance performance, as well as the influence of sex and CYP1A2 genotype, in healthy resistance training-naïve older adults.

Conditions

Caffeine; Placebo - Control

Outcome Measures

Primary Outcomes (4)

• Mean velocity at different %1RM

  Mean velocity at different %1RM

  Through study completion, an average of 3 weeks

• Number of repetitions performed during 1 set at 65%1RM until task failure

  In bench press and back squat exercises

  Through study completion, an average of 3 weeks

• Bar velocity deplacement performed in 1 set at 65%1RM until task failure

  In bench press and back squat exercises

  Through study completion, an average of 3 weeks

• handgrip and isometric mid-thigh pull tests

  N generated

  Through study completion, an average of 3 week

Secondary Outcomes (3)

• CYP1A2 polymorphism

  Before the beginning of the trial

• Mood state (tension, depression, anger, vigor, fatigue and confusion)

  Through study completion, an average of 3 weeks

• Adverse effects

  Through study completion, an average of 3 weeks

Study Arms (2)

Caffeine

EXPERIMENTAL

Acute caffeine intake (3 mg/kg)

Dietary Supplement: Caffeine

Placebo

PLACEBO COMPARATOR

Placebo (3 mg/kg maltodextrin)

Dietary Supplement: Placebo

Interventions

Caffeine DIETARY_SUPPLEMENT

Acute caffeine intake (3 mg/kg)

Caffeine

Placebo DIETARY_SUPPLEMENT

Placebo (3 mg/kg maltodextrin)

Placebo

Eligibility Criteria

• Age: 55 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 55 years.
• Body mass index (BMI) lower than 25 kg/m².
• Physically active subjects (≥150 min/week of moderate exercise).
• Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from performing physical exercise.
• Participants capable of performing the tests.

You may not qualify if:

• History of neuromuscular, cardiac, or diseases that could affect liver or muscle metabolism.
• Use of drugs or other stimulants that interfere with caffeine intake and intestinal absorption during the tests and study.
• Body mass index (BMI) ≥ 25 kg/m².
• Having undergone prolonged periods of forced physical inactivity during the 6 months prior to the study. • Performing strenuous exercise within 48 hours prior to the tests.
• Failing to replicate the same food intake on the two experimental days.
• Consuming caffeine after 6 PM on the day prior to training or testing.

Sponsors & Collaborators

• University of Alcala: lead

Study Sites (1)

Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá

Alcalá de Henares, Madrid, 28805, Spain

Location

MeSH Terms

Interventions

Caffeine

Intervention Hierarchy (Ancestors)

Xanthines; Alkaloids; Heterocyclic Compounds; Purinones; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: Statisian
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: July 13, 2026
• First Posted: July 17, 2026
• Study Start: January 10, 2024
• Primary Completion: December 21, 2025
• Study Completion: April 24, 2026
• Last Updated: July 21, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will share

Locations

ES (1)